MARKET

RGNX

RGNX

Regenxbio
NASDAQ

Real-time Quotes | Nasdaq Last Sale

29.14
-3.24
-10.01%
Closed 16:59 04/01 EDT
OPEN
30.74
PREV CLOSE
32.38
HIGH
31.65
LOW
28.70
VOLUME
453.30K
TURNOVER
--
52 WEEK HIGH
59.98
52 WEEK LOW
20.03
MARKET CAP
1.08B
P/E (TTM)
-11.2836
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average RGNX stock price target is 75.50 with a high estimate of 150.00 and a low estimate of 35.00.

EPS

RGNX News

More
  • FDA OKs new hemophilia treatment
  • Seeking Alpha - Article · 16h ago
  • The Daily Biotech Pulse: InflaRx Begins Human Testing For COVID-induced Pneumonia, Chembio, Becton Dickinson Launch Coronavirus Tests
  • Benzinga · 22h ago
  • Regenxbio: A Growth Stock For The Coronavirus Bear Market
  • Seeking Alpha - Article · 23h ago
  • Regenxbio teams up with Ultragenyx in gene therapy for rare metabolic disorder
  • seekingalpha · 1d ago

Industry

Biotechnology & Medical Research
-4.52%
Pharmaceuticals & Medical Research
-2.91%

Hot Stocks

Symbol
Price
%Change

About RGNX

REGENXBIO Inc. is a clinical-stage biotechnology company. The Company's gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases. Its product candidate, RGX-314, is meant for the treatment of wet age-related macular degeneration (wet AMD). Its product candidate, RGX-501, is meant for the treatment of homozygous familial hypercholesterolemia (HoFH). It is also developing product candidates, such as RGX-111 and RGX-121, to address the neurological symptoms of two severe genetic lysosomal storage diseases, Mucopolysaccharidosis Type I (MPS I) and Mucopolysaccharidosis Type II (MPS II), respectively. Its product candidates utilize viral vectors from its gene delivery platform, NAV Technology Platform.
More

Webull offers kinds of Regenxbio Inc stock information, including NASDAQ:RGNX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, RGNX stock news, and many more online research tools to help you make informed decisions.